Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

HOPE Prostate is an observational study that aims at promoting research against metastatic prostate cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic prostate cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease, and to provide a blood sample and an archival tumor biopsy. In HOPE Prostate these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will try to enumerate future therapeutic options that match patient history and his genomic profile. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic prostate cancer patients.

NCT Number	NCT05885009
Lead Sponsor	SOLTI Breast Cancer Research Group Collaborators: Pfizer, AstraZeneca, Merck Sharp & Dohme LLC, Advanced Accelerator Applications, Astellas Pharma Inc, Guardant Health, Inc.
Conditions	Metastatic Prostate Cancer
Enrollment	240 participants
Start Date	2023-03-28
Primary Completion	2026-03-28 (estimated)
Study Completion	2028-03-28 (estimated)
Updated on ClinicalTrials.gov	2025-08-06